Dextromethorphan Pediatric Acute Cough Study

NCT ID: NCT02651116

Last Updated: 2021-04-28

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE4
• Total Enrollment: 131 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-02-25
• Study Completion Date: 2020-03-19

Brief Summary

This is a placebo-controlled, double-blind, randomized, parallel group pilot study in approximately 150 subjects to evaluate the efficacy of dextromethorphan hydrobromide (DXM) on acute cough in a pediatric population. Subjects will be otherwise healthy males and females aged 6-11 inclusive who are experiencing acute cough as a symptom of common cold or upper respiratory tract infection. Subjects must have had onset of symptoms within 3 days of screening and qualify based on physical exam and symptom questionnaire. Eligible subjects will be given a single-blind placebo, and fitted with a cough counting device for a 2 hour run-in period. Qualifying subjects will be stratified by age and then randomized to either DXM or placebo in a 1:1 ratio and fitted with the cough recording device for the first 24 hours of treatment. Subjects will receive approximately 9 doses of investigational product over the course of the 4 day study and will complete patient reported outcome questions before the morning and afternoon doses. Subjects will return to the study site on Day 2 to remove the cough recorder and on Day 4 (+ 2 days) to complete the final visit. A review of any reported adverse events will also be completed.

Detailed Description

This is a placebo-controlled, double-blind, randomized, parallel group pilot study in approximately 150 subjects to evaluate the efficacy of dextromethorphan hydrobromide DXM) on acute cough in a pediatric population. Subjects will be otherwise healthy males and females aged 6-11 inclusive who are experiencing acute cough as a symptom of common cold or upper respiratory tract infection. Subjects must have had onset of symptoms within 3 days of screening and qualify based on physical exam and symptom questionnaire. Eligible subjects will be given a single-blind placebo, and fitted with a cough counting device for a 2 hour run-in period. Qualifying subjects will be stratified by age and then randomized to either DXM or placebo in a 1:1 ratio and fitted with the cough recording device for the first 24 hours of treatment. Subjects will receive approximately 9 doses of investigational product over the course of the 4 day study and will complete patient reported outcome questions before the morning and afternoon doses. Subjects will return to the study site on Day 2 to remove the cough recorder and Day 4 (+2 days) to complete the final visit. A review of any reported adverse events will also be completed. Validated Patient Reported Outcomes (PRO) used in the study include morning cough assessment, afternoon cough assessment, Child Global Question, and Child Cold Symptom Checklist

Conditions

Cough

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Dextromethorphan Hydrobromide

15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide

Group Type: EXPERIMENTAL

Dextromethorphan Hydrobromide

Intervention Type: DRUG

15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide

Cough recording device

Intervention Type: DEVICE

FDA approved device validated for use in adults and children

Placebo

10 mL of Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

10 mL Placebo

Cough recording device

Intervention Type: DEVICE

FDA approved device validated for use in adults and children

Interventions

Dextromethorphan Hydrobromide

15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide

Intervention Type: DRUG

Placebo

10 mL Placebo

Intervention Type: DRUG

Cough recording device

FDA approved device validated for use in adults and children

Intervention Type: DEVICE

Other Intervention Names

DXM; VitaloJAK

Eligibility Criteria

Inclusion Criteria

• Generally healthy male or female children/adolescents ages 6 to 11 years, inclusive.
• Subject has an acute cough and other symptoms consistent with a common cold/acute upper respiratory tract infection (URTI) diagnosis as deemed by the investigator or qualified designee based on findings from medical history review, full physical examination and vital signs.
• The onset of symptoms must be no more than 3 days prior to Visit 1, as determined by the subject or parent/legally acceptable representative.
• Qualifying response on the Child Cold Symptom Checklist.
• Parent/legally acceptable representative, and subject agrees the subject will not use any other cough or cold treatments during the study.

Exclusion Criteria

• A subchronic, or chronic cough due to any condition other than an URTI or common cold as established by the investigator, nurse practitioner, or physician's assistant, in accordance with the American College of Chest Physicians' (ACCP) Guidelines for Diagnosis and Management of Cough. Special attention should be paid to highly prevalent conditions commonly presenting with cough such as asthma, rhinitis, or gastroesophageal reflux disease (GERD).
• Symptoms of runny nose, stuffy nose, sore throat, or sneezing due to any condition other than URTI or common cold (eg, seasonal or perennial allergic rhinitis, sinusitis, strep throat, vasomotor rhinitis, etc.) as established by the investigator.
• An acute cough that occurs with excessive phlegm (mucus) or is chronic such as occurs with smoking, asthma, bronchitis, allergies, or a gastroesophageal condition (eg, acid reflux and GERD) or history of such a cough.
• Clinical features of a complication of the common cold during the physical examination at screening (eg, otitis media, sinusitis, or pneumonia) with or without the need for systematic antibiotics.
• Pneumonia (active or with a symptom-free period of <30 days), asthma (active or with a symptom-free period of <1 year), or other significant pulmonary diseases.
• Fever greater than 39ºC (102ºF oral temperature) at the time of screening if, in the judgment of the investigator, the individual is too ill to participate in the study or the fever is due to reasons other than URTI.
• Signs of dehydration (as may be due to vomiting, diarrhea, or lack of fluid intake) during the physical examination at screening.
• Diabetes or hypoglycemic disorders.
• Known contraindications to the investigational product or acetaminophen (APAP).
• Sitting blood pressure reading at or above the limits as documented in the protocol.
• Obstructive sleep apnea caused by enlarged tonsils and adenoids, low muscle tone, or allergies.
• History of known or suspected allergy or hypersensitivity to dextromethorphan (DXM) or APAP, or any of the non medicinal ingredients contained in the single-blind confection, double-blind investigational products, or APAP.
• History of taking any of the specified prohibited medications or products within the corresponding washout periods prior to taking the first dose of investigational product.
• History of taking a medication that is sedating within the past 24 hours prior to screening (eg sedatives, hypnotics, tranquilizers, anticonvulsants, benzodiazepines, and clonidine).
• Subject has a sibling contemporaneously participating in this study.

Randomization Criteria:

• Subjects must complete the 2 hour ambulatory cough counting baseline run-in recording period and must return to the study site for randomization at least 2 hours after the recording started.
• Subjects whose equipment failed, preventing collection of cough count data for at least 2 hours during the Baseline Run-in Period, or those who took off the device during this period will be excluded from further study participation.
• Subjects who do not return to the study site (before 3:30 pm) in time for the afternoon dose will not be randomized.
• Qualifying response on Child Global Question

• Minimum Eligible Age: 6 Years
• Maximum Eligible Age: 11 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pfizer

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Avail Clinical Research, LLC

DeLand, Florida, United States

Clinical Associates of Orlando LLC

Orlando, Florida, United States

Elite Clinical Trials LLLP

Blackfoot, Idaho, United States

Advanced Clinical Research

Meridian, Idaho, United States

Kentucky Pediatric/Adult Research

Bardstown, Kentucky, United States

All Children Pediatrics

Louisville, Kentucky, United States

Bluegrass Clinical Research, Inc

Louisville, Kentucky, United States

MedPharmics, LLC

Metairie, Louisiana, United States

Midwest Children's Health Research Institute

Lincoln, Nebraska, United States

Meridian Clinical Research LLC

Omaha, Nebraska, United States

Rapid Medical Research, Inc

Cleveland, Ohio, United States

Coastal Pediatric Associates

Charleston, South Carolina, United States

Coastal Pediatric Associates

Mt. Pleasant, South Carolina, United States

Carolina Ear, Nose & Throat Clinic/CENTRI Inc.

Orangeburg, South Carolina, United States

Meridian Clinical Research, LLC

Dakota Dunes, South Dakota, United States

Texas Health Care, PLLC

Fort Worth, Texas, United States

Ventavia Research Group, LLC

Fort Worth, Texas, United States

Advanced Clinical Research

West Jordan, Utah, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://pmiform.com/clinical-trial-info-request?StudyID=A6531002

To obtain contact information for a study center near you, click here.

Other Identifiers

CHPA DXM

Identifier Type: OTHER

Identifier Source: secondary_id

A6531002

Identifier Type: -

Identifier Source: org_study_id